Nortriptyline for treatment-resistant depression

Journal of Clinical Psychiatry

Volumn 64, Issue 1, 2003, Pages 35-39

  Nierenberg, Andrew A ^a   Papakostas, George I ^a   Petersen, Timothy ^a   Kelly, Karen E ^a   Iacoviello, Brian M ^a   Worthington, John J ^a   Tedlow, Joyce ^a   Alpert, Jonathan E ^a   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; DESIPRAMINE; IMIPRAMINE; LITHIUM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THYROID HORMONE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ANALYSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0037262462     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0108     Document Type: Article

References (42)

1. Nierenberg AA, White K. What next? a review of pharmacologic strategies for treatment resistant depression. Psychopharmacol Bull 1990;26: 429-460
2. Nierenberg AA, Amsterdam JD. Treatment resistant depression: definition and treatment approaches. J Clin Psychiatry 1990;51(suppl 6):39-47
3. Burrows GD, Norman TR, Judd FK. Definition and differential diagnosis of treatment resistant depression. Int Clin Psychopharmacol 1994;9 (suppl 2):5-10
4. Klein DE, Gittelman AH. Diagnosis and Treatment of Psychiatric Disorders: Adults and Children. Baltimore, Md: Williams & Wilkins; 1980
5. Keller MB, Klerman GL, Lavori PW. Long term outcome of episodes of major depression. JAMA 1984;252:788-792
6. Fava M, Kaji J, Davidson K. Pharmacologic strategies for treatment-resistant major depression. In: Pollack MH, Otto MW, Rosenbaum JF, eds. Challenges in Clinical Practice: Pharmacologic and Psychosocial Strategies. New York, NY: Guilford Publications; 1996:1-12
7. Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992;49:809-816
8. Price LH, Charney DS, Heninger GR. Variability of response to lithium augmentation in refractory depression. Am J Psychiatry 1986;143: 1387-1392
9. Roose SP, Glassman AH, Attia E, et al. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994;151:1735-1739
10. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled double blind study. Am J Psychiatry 2000;157: 351-359
11. Perry PJ. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J Affect Disord 1996;39:1-6
12. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine: a controlled multicenter study. Psychopharmacology (Berl) 1986;90:131-138
13. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-299
14. Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRI and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Br J Psychiatry 1997;170:120-127
15. Mischoulon D, Nierenberg AA, Kizilbash L, et al. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can J Psychiatry 2000;45:476-481
16. Thase ME, Frank E, Mallinger AG, et al. Treatment of imipramine-resistant recurrent depression, 3: efficacy of monoamine oxidase inhibitors. J Clin Psychiatry 1992;53:5-11
17. Spitzer RL, Williams JB, Gibbon M, et al. Structured Clinical Interview for DSM-III-R Patient Edition with Psychotic Screen (SCID-III-R with Psychotic Screen, Version 1.0). Washington, DC: American Psychiatric Press Inc; 1989
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
19. Nierenberg AA, Keck PE, Samson J, et al. Methodologic considerations for the study of treatment-resistant depression. In: Amsterdam JD, ed. Refractory Depression. New York, NY: Raven Press; 1991:1-12
20. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
21. Borenstein M, Rothstein H, Cohen J. Power and Precision. Hillsdale, NJ: Lawrence Erlbaum Associates; 1997
22. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995;310:1433-1438
23. Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993;306: 683-687
24. McGrath PJ, Stewart JW, Harrison W, et al. Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacol Bull 1987;23:169-172
25. Kocsis J, Thase ME, Keller MB, et al. Double-blind crossover antidepressant study: sertraline versus imipramine. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology; Dec 11-14, 1995; San Juan, Puerto Rico
26. Volz HP, Faltus F, Magyar I, et al. Brofaromine in treatment-resistant depressed patients: a comparative trial versus tranylcypromine. J Affect Disord 1994;30:209-217
27. Nolen WA, Haffmans PM, Bouvy PF, et al. Monoamine oxidase inhibitors in resistant major depression: a double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. J Affect Disord 1993;28:189-197
28. Nolen WA, Van de Putte JJ, Dijken WA, et al. L-5HTP in depression resistant to re-uptake inhibitors: an open comparative study with tranylcypromine. Br J Psychiatry 1985;147:16-22
29. Thase ME, Blomgren SL, Birkett MA, et al. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997;58:16-21
30. Joffe RT, Levitt AJ, Sokolov STH, et al. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 1996;57:114-115
31. Zarate CA Jr, Kando JC, Tohen M, et al. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry 1996;57:67-71
32. Nolen WA, Van de Putte JJ, Dijken WA, et al. Treatment strategy in depression, 1: non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxarnine. Acta Psychiatr Scand 1988;78:668-675
33. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Br J Psychiatry 1999;175:12-16
34. De Montigny C, Silverstone P, Debonnel G, et al. Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. J Clin Psychopharmacol 1999;19:401-406
35. Stern WC, Harto-Truax N, Bauer N. Efficacy of bupropion in tricyclicresistant or intolerant patients. J Clin Psychiatry 1983;44:148-152
36. Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry 1993;54:459-465
37. Goodnick PJ, Sandoval R, Brickman A, et al. Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome. Biol Psychiatry 1992;32: 834-838
38. McGrath PJ, Fava M, Stewart JW, et al. Bupropion sustained release for SSRI-resistant major depression. Presented at the 153rd annual meeting of the American Psychiatric Association; May 13-18, 2000; Chicago, Ill
39. Fava M, Dunner DL, Greist JH, et al. An open-label study with mirtazapine in depressed patients who are SSRI treatment failures. Presented at the 152nd annual meeting of the American Psychiatric Association; May 15-20, 1999; Washington, DC
40. Folkerts HW, Michael N, Tolle R, et al. Electroconvulsive therapy versus paroxetine in treatment-resistant depression: a randomized study. Acta Psychiatr Scand 1997;96:334-342
41. Nierenberg AA, Feighner JP, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-423
42. Rush AJ, George MS, Sackeim HA, et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry 2000;47:276-286